Ontology highlight
ABSTRACT: Background
Two novel genetic polymorphisms on chromosome 6q23 are associated with susceptibility to rheumatoid arthritis (RA). Both polymorphisms (rs6920220 and rs10499194) reside in a region close to the gene encoding tumour necrosis factor alpha-induced protein 3 (TNFAIP3). TNFAIP3 is a negative regulator of NF-kappaB and is involved in inhibiting TNF-receptor-mediated signalling effects. Interestingly, the initial associations were detected in patients with longstanding RA. However, no association was found for rs10499194 in a Swedish cohort with early arthritis. This might be caused by over-representation of patients with severe disease in cohorts with longstanding RA.Objective
To analyse the effect of the 6q23 region on the rate of joint destruction.Methods
Five single nucleotide polymorphisms in 6q23 were genotyped in 324 Dutch patients with early RA. Genotypes were correlated with progression of radiographic joint damage for a follow-up time of 5 years.Results
Two polymorphisms (rs675520 and rs9376293) were associated with severity of radiographic joint damage in patients positive for anti-citrullinated protein/peptide antibodies (ACPA). Importantly, the effects were present after correction for confounding factors such as secular trends in treatment.Conclusions
These data associate the 6q23 region with the rate of joint destruction in ACPA+ RA.
SUBMITTER: Scherer HU
PROVIDER: S-EPMC2927680 | biostudies-literature | 2010 Mar
REPOSITORIES: biostudies-literature
Scherer Hans Ulrich HU van der Linden Michael P M MP Kurreeman Fina A S FA Stoeken-Rijsbergen Gerrie G Cessie Saskia le Sl Huizinga Tom W J TW van der Helm-van Mil Annette H AH Toes René E M RE
Annals of the rheumatic diseases 20090414 3
<h4>Background</h4>Two novel genetic polymorphisms on chromosome 6q23 are associated with susceptibility to rheumatoid arthritis (RA). Both polymorphisms (rs6920220 and rs10499194) reside in a region close to the gene encoding tumour necrosis factor alpha-induced protein 3 (TNFAIP3). TNFAIP3 is a negative regulator of NF-kappaB and is involved in inhibiting TNF-receptor-mediated signalling effects. Interestingly, the initial associations were detected in patients with longstanding RA. However, n ...[more]